Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.54 USD
-0.10 (-0.86%)
Updated Jul 26, 2024 01:54 PM ET
After-Market: $11.52 -0.02 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Avalo Therapeutics, Inc. (AVTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$35.00 | $35.00 | $35.00 | 200.69% |
Price Target
Only one analyst offered a short-term price target of $35.00 for Avalo Therapeutics, Inc. This represents an increase of 200.69% from the last closing price of $11.64.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Avalo Therapeutics, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/16/2024 | Not Identified | Not Identified | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $35.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 252 |
Current Quarter EPS Est: | -6.70 |